REPL Stock Collapses As FDA Rejection Triggers Downgrades

Replimune Group Inc. faces heavy selling after negative trial and funding headlines, with stocks have been trading down by -15.79 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading REPL

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

The FDA issued a second Complete Response Letter for Replimune’s BLA for RP1 plus nivolumab in anti–PD-1-failed melanoma, again finding the IGNYTE trial inadequate to demonstrate effectiveness.
Following the latest FDA rejection of RP1 in melanoma, shares collapsed by about 62–64% on massive volume, and several analysts now see no clear regulatory path forward for the asset.
Multiple firms including H.C. Wainwright, Wedbush, JPMorgan, Jefferies, Cantor Fitzgerald, Piper Sandler and Leerink downgraded Replimune, with several slashing price targets to $2 and the overall analyst consensus now at Hold with a mean price target around $4.
Jefferies noted that management will no longer develop RP1 absent accelerated approval, heightening uncertainty over Replimune’s future strategy.
Law firms Johnson Fistel and Pomerantz LLP launched investigations into potential securities law violations after the second Complete Response Letter and the resulting 64% stock price collapse.

Weekly Update Apr 20 – Apr 24, 2026: On Saturday, April 25, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending down by -15.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

Replimune is now a distressed small-cap oncology developer with a challenged lead asset and deeply negative returns on capital (ROA LTM -67%, ROE LTM -91%, ROIC around -50%). With no revenue, the business is entirely cash-burn driven: FY cash from operations was about -$66M against free cash flow of roughly -$66M, dominated by $53M R&D. Liquidity is strong near term (cash and investments ~$269M, current ratio 5.6, modest leverage with total debt-to-equity 0.36), implying ~3–4 years of runway at current burn.

Technically, the stock is in a violent downtrend following the CRL-driven gap, with price collapsing into the low single digits and heavy volume confirming institutional distribution. Last week’s sequence from 2.09 to 2.40 shows a tentative bounce but lower high versus pre-CRL levels, consistent with a bear-flag/pause rather than a trend reversal. On intraday 5-minute candles, liquidity is adequate but volatile; $2.00 is the key actionable pivot—below it, short bias is favored, while sustained closes above $2.50 would be needed to signal any credible short-covering rally.

More Breaking News

The second FDA Complete Response Letter for RP1 plus nivolumab effectively removes the core melanoma value driver, triggering multiple downgrades and target cuts to $2–$4, well below prior consensus and sector biotech benchmarks. Legal overhang from securities investigations further depresses risk appetite. Versus healthcare and biotech indices, REPL now trades as a binary, asset-salvage story rather than a growth platform. My definitive view: avoid on the long side; fair value resides around $2 with resistance near $2.50 and support at $1.50, skewed to further downside if pipeline reprioritization disappoints.

Quick Financial Overview

Replimune Group Inc. is trading in the low single digits after the FDA’s second Complete Response Letter for RP1. Weekly data show REPL opening near $2.09 and grinding between roughly $1.83 and $2.88 over recent sessions, with a latest close around $2.40. That is consistent with a name that has already absorbed a 62–64% collapse and is now trying to stabilize in a new, much lower range.

Intraday, the 5‑minute candle shows an open near $2.70, a push toward $2.78, and a hard fade down to about $2.37 before closing around $2.42. That intraday pattern reflects overhead supply: strength is being sold into quickly, which is typical after a shock gap-down where trapped holders use any bounce to exit. For short-term traders, that $2.70–$2.80 zone now acts as clear near-term resistance.

On the fundamentals, REPL remains a classic high-burn biotech. The latest quarterly numbers show about -$70.9M in net income and operating cash outflow near -$65.9M, driven mainly by $53.1M of research expense. Yet the balance sheet still carries roughly $124.7M in cash and about $269.1M including short-term investments, with a strong current ratio of 5.6 and modest debt, so near-term liquidity is not the issue. The problem is value creation: returns on equity and assets are deeply negative, and now the lead program RP1 has no clear path, forcing traders to price the stock off a damaged pipeline and remaining cash.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!